Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345183 · ClinicalTrials.gov registry record
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
A clinical trial of Advanced Renal Cell Carcinoma (aRCC), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 327
- Enrollment target
- 1
- Study location
NCT06345183: Completed study of Advanced Renal Cell Carcinoma (aRCC), sponsored by Bristol-Myers Squibb.
NCT06345183 is a study of Advanced Renal Cell Carcinoma (aRCC) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 327 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06345183, a study of Advanced Renal Cell Carcinoma (aRCC), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 327 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
Conditions Studied
Interventions
- COMBINATION_PRODUCT Nivolumab + Ipilimumab combination therapy
- COMBINATION_PRODUCT Pembrolizumab + Lenvatinib combination therapy
Study Locations (1)
Ohio
- Cardinal Health - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2024-04-04 |
What the finished NCT06345183 record still lists
NCT06345183 is an observational study that tracks outcomes without assigning an intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Advanced Renal Cell Carcinoma (aRCC) appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab + Ipilimumab combination therapy is the first listed.
NCT06345183 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06345183 about?
NCT06345183 is a clinical study titled "Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients". This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
What is the current status of trial NCT06345183?
This trial is currently completed. The enrollment target is 327 participants. The study started on 2024-02-19. Estimated completion is 2024-04-04.
What conditions does trial NCT06345183 study?
This clinical trial studies the following conditions: Advanced Renal Cell Carcinoma (aRCC).
What interventions are being tested in trial NCT06345183?
The interventions under investigation include: Nivolumab + Ipilimumab combination therapy (COMBINATION_PRODUCT), Pembrolizumab + Lenvatinib combination therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06345183?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345183 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Renal Cell Carcinoma (aRCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI